Table 2.

Adverse events during therapy in all 54 treated patients.

Adverse Event		Grade 1		Grade 2		Grade 3		Grade 4		Any Grade
		N	%	N	%	N	%	N	%	N	%
Hematologic
Neutropenia		6	11	14	26	11	20	4	7	35	65
Febrile neutropenia		0	0	0	0	2	4	0	0	2	4
Anemia		21	39	11	20	2	4	1	2	35	65
Thrombocytopenia		15	28	3	6	1	2	0	0	19	35
Infection		0	0	15	28	4	7	0	0	19	35
Gastrointestinal
Diarrhea		30	56	10	19	3	6	0	0	43	80
Nausea		23	43	16	30	1	2	0	0	40	74
Vomiting		16	30	5	9	4	7	0	0	25	46
Mucositis		20	37	3	6	1	2	0	0	24	44
Constitutional
Fatigue		16	30	19	35	9	17	1	2	45	83
Anorexia		17	31	10	19	1	2	0	0	28	52
Taste disturbance		14	26	10	19	0	0	0	0	24	44
Pain		21	39	11	20	4	7	3	6	39	72
Arthralgia		18	33	6	11	0	0	0	0	24	44
Neurologic
Headache		15	28	4	7	3	6	0	0	22	41
Neuropathy		14	26	11	20	12	22	0	0	37	69
Muscle weakness (Generalized)		9	17	3	6	2	4	0	0	14	26
Dizziness		13	24	3	6	2	4	0	0	18	33
Renal/Metabolic
Creatinine		4	7	3	6	0	0	0	0	7	13
AST		15	28	3	6	0	0	0	0	18	33
ALT		11	20	4	7	0	0	0	0	15	28
Hypocalcemia		13	24	2	4	0	0	1	2	16	30
Hypokaelemia		5	9	0	0	1	2	0	0	6	11
Hyponatremia		13	24	0	0	1	2	0	0	14	26
Proteinuria		1	2	0	0	0	0	1	2	2	4
Vascular
Hypertension		6	11	4	7	4	7	0	0	14	26
Thrombosis		0	0	1	2	4	7	2	4	7	13
Epistaxis		29	54	2	4	1	2	0	0	32	59
Skin
Rash		12	22	8	15	0	0	0	0	20	37
Pulmonary
Dyspnea		13	24	3	6	6	11	0	0	22	41